Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gyre Therapeutics (STU:L9S) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Gyre Therapeutics Net Margin % Related Terms
Gyre Therapeutics Net Margin % Historical Data
* Premium members only.
The historical data trend for Gyre Therapeutics's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:L9S vs OCS, RIGL, SGP: Net Margin % Comparison
For the Biotechnology subindustry, Gyre Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gyre Therapeutics Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's Net Margin % distribution charts can be found below:
* The bar in red indicates where Gyre Therapeutics's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gyre Therapeutics (STU:L9S) has a Net Margin % of -36.44% as of Jun. 2026. Net margin is the ratio of total net income to net sales. View historical data on Gyre Therapeutics and its competitors. According to the industry distribution chart, Gyre Therapeutics ranks #343 out of 944 companies in the Biotechnology industry, placing it in the top 36.3%.
Is Gyre Therapeutics' Net Margin % too high?
Gyre Therapeutics' current Net Margin % is -36.44%. Based on the distribution chart, Gyre Therapeutics ranks #343 out of 944 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Gyre Therapeutics has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Gyre Therapeutics' Net Margin % compare to OCS and RIGL?
According to the Biotechnology industry distribution chart, Gyre Therapeutics ranks #343 out of 944 companies for Net Margin %. This puts Gyre Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Gyre Therapeutics and its competitors. Gyre Therapeutics's current Net Margin % is -36.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gyre Therapeutics stock overvalued right now?
Gyre Therapeutics (STU:L9S) has a current Net Margin % of -36.44%. The stock's GF Value™ is €7.95, compared to a current price of €5.75 — trading 27.7% below its estimated fair value. The current Net Margin % is -36.44%. Gyre Therapeutics' overall GF Score™ is 39/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Gyre Therapeutics (STU:L9S), the current Net Margin % is -36.44% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gyre Therapeutics (STU:L9S) Overvalued in 2026?
Based on GuruFocus' analysis, Gyre Therapeutics stock appears to be undervalued.
The current stock price of €5.75 is trading 27.7% below its estimated GF Value™ of €7.95.
Key valuation signals for STU:L9S:
Net Margin %: -36.44%
GF Value™: €7.95 vs. price of €5.75 (27.7% below fair value)
No single metric tells the full story. See the STU:L9S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
39GF Score
Get the complete analysis for STU:L9S
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:L9S has been successfully added to your 
